

Readers we surveyed ...

97%

said the content DTB published was practical to their work

95%

said they trusted the content

93%
rated DTB's content as good or excellent

92%

liked the concise nature of content published in DTB





1,600+

Sources: Google Analytics 2022 2021 DTB readership survey

Founding Editor: Andrew Herxheimer



1962 <u>First issue of the British edition of The Medical Letter on Drugs and Therapeutics published</u>

1963 First issue of Drug and Therapeutics Bulletin published

1965 <u>Highlighted the dangers associated with phenacetin</u>



1973 Called for more warnings on the effect of tetracyclines on children's teeth

1977 <u>Highlighted the need for listing drugs by their generic names</u>

1979 Argued for removal or restriction of prednisone



1983 <u>Campaigned against excessive promotional claims made</u> for tiaprofenic acid

1984 <u>Argued for greater use of clinical trial registries and a central body to allocate public funding of clinical trials</u>
1985 <u>Suggested that patient information leaflets should be provided for all medicines</u>



1992 - Joe Collier appointed Editor

1994 Article on using medicines in schools led to national guidelines

1994 Argued against using aspirin for primary prevention of CVD

1997 <u>Called for greater restrictions on off-label use of drugs in children</u>

2000 <u>Provided early warning on the therapeutic limitations of</u> coxib drugs



2001 <u>Highlighted limitations in the evidence for using</u> sibutramine

2004 Ike Iheanacho appointed Editor

2005 <u>Published "Drugs for the doctor's bag" articles that</u> became standard advice

2006 BMJ started publishing DTB



2012 James Cave appointed Editor

2014 Argued for the abolition of the NHS prescription charge in England

2015 Called for minimum unit pricing for alcohol



2020 <u>Highlighted limitations of the evidence for melatonin on symptoms of jet lag</u>

2020 <u>Called for easier access to aspirin for prevention of pre-eclampsia</u>

2021 <u>Called for better information for the public on the safety and effectiveness of Covid-19 vaccines</u>
 2021 <u>Called for greater scrutiny of the evidence for aducanumab for Alzheimer's disease</u>



dtb.bmj.com

#DTB60

BMJ